Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 12—December 2021
CME ACTIVITY - Synopsis

Clinical Characteristics of Corynebacterium Bacteremia Caused by Different Species, Japan, 2014–2020

Ryosuke YamamuroComments to Author , Naoto Hosokawa, Yoshihito Otsuka, and Ryosuke Osawa
Author affiliation: Kameda Medical Center, Chiba, Japan

Main Article

Table 3

Antimicrobial susceptibility testing of Corynebacterium species isolated from blood culture, Japan, 2014–2020*

Species Susceptible/tested (%)
PEN CRO MEM GEN CIP MIN CLI ERY VAN LZD†
C. striatum, n = 67
14/67 (21)
5/67 (7)
17/67 (25)
59/67 (88)
3/67 (4)
67/67 (100)
8/67 (12)
13/67 (19)
67/67 (100)
4/4 (100)
C. jeikeium, n = 14
0/14 (0)
0/14 (0)
5/14 (36)
5/14 (36)
0/14 (0)
14/14 (100)
0/14 (0)
0/14 (0)
14/14 (100)
3/3 (100)
Other species, n = 34
27/34 (79)
22/34 (65)
31/34 (91)
30/34 (88)
10/34 (29)
34/34 (100)
6/34 (18)
16/34 (47)
34/34 (100)
2/2 (100)
All, n = 115 41/115 (36) 27/115 (23) 53/115 (46) 94/115 (82) 13/115 (11) 115/115 (100) 14/115 (12) 29/115 (25) 115/115 (100) 9/9 (100)

*CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; ERY, erythromycin; GEN, gentamicin; LZD, linezolid; MEM, meropenem; MIN, minocycline; PEN, penicillin; VAN, vancomycin.

†Antimicrobial susceptibility testing for linezolid was only performed if requested by physicians.

Main Article

Page created: October 06, 2021
Page updated: November 17, 2021
Page reviewed: November 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external